Integrated Landscape, Value, and Pricing Assessment for a Development-Stage Oncology Product

An emerging biopharma company was developing its first product, an oncology therapy that would be the first of its kind in its targeted cancer type. The therapy had received a fast-track designation and the company needed to better understand the access landscape to inform its pricing at launch.

Our team began by developing a comprehensive assessment of the market access landscape for the product. This involved reviewing the client’s existing materials, conducting secondary research, and facilitating working sessions with the client to align on our access hypotheses, as well as data gaps that needed to be filled. Next, we conducted primary research with a wide range of external stakeholders including payers, organized customers, and providers. This research deepened our understanding of the landscape, helped identify key value drivers, enabled us to refine the target product profile, and identified additional evidence needed to improve price-access potential. We then synthesized our findings and developed draft pricing recommendations. We also outlined the implications for access and adoption. After refining the deliverable with the client team, we moved forward with helping them finalize their pricing philosophy and strategy.

As a result of our work, the company’s leaders had the information they needed to move forward with confidence. Blue Matter was retained to provide additional support and guidance as the product advanced through the development process.